Fishman Corey N. 4
4 · BIOSPECIFICS TECHNOLOGIES CORP · Filed Dec 2, 2020
Insider Transaction Report
Form 4
Fishman Corey N.
Director
Transactions
- Disposition to Issuer
Common Stock, $0.001 par value
2020-12-02−2,018→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2020-12-02$32.87/sh−6,000$197,220→ 0 totalExercise: $55.63Exp: 2030-05-01→ Common Stock (6,000 underlying)
Footnotes (2)
- [F1]Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 2,018 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $178,593.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).
- [F2]Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in three equal annual installments following the grant date (May 1, 2020), were canceled in exchange for a cash payment of $197,220.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.